Achilles Therapeutics PLC ADR (ACHL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Achilles Therapeutics PLC ADR stock (ACHL) is currently trading at $1.48. Analyst consensus price target for ACHL is $0.50. WallStSmart rates ACHL as Sell.
- ACHL PE ratio analysis and historical PE chart
- ACHL PS ratio (Price-to-Sales) history and trend
- ACHL intrinsic value — DCF, Graham Number, EPV models
- ACHL stock price prediction 2025 2026 2027 2028 2029 2030
- ACHL fair value vs current price
- ACHL insider transactions and insider buying
- Is ACHL undervalued or overvalued?
- Achilles Therapeutics PLC ADR financial analysis — revenue, earnings, cash flow
- ACHL Piotroski F-Score and Altman Z-Score
- ACHL analyst price target and Smart Rating
Achilles Therapeutics PLC ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Achilles Therapeutics PLC ADR (ACHL) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Achilles Therapeutics PLC ADR (ACHL) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
83.10% of shares held by major funds and institutions
Achilles Therapeutics PLC ADR (ACHL) Areas to Watch (2)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Achilles Therapeutics PLC ADR (ACHL) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.61) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap. Profitability pressure is visible in Return on Equity at -52.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -52.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACHL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Achilles Therapeutics PLC ADR (ACHL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Achilles Therapeutics PLC ADR operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Achilles Therapeutics PLC ADR.
Bottom Line
Achilles Therapeutics PLC ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Achilles Therapeutics PLC ADR(ACHL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.